X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Linaclotide is a guanylate cyclase-C (GC-C) agonist that is thought to work in two ways based on nonclinical studies. Linaclotide binds to the GC-C receptor locally within the intestinal epithelium.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Total of 27 abstracts AbbVie leadership in advancing research and standard of care across multiple gastroenterological condition, also presentations include analyses of Phase 3 study programs for RINVOQ (upadacitinib) in ulcerative colitis and risankizumab in Crohn's disease.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
EMWA 2024
Not Confirmed
Contact Supplier
Details:
Pursuant to the terms of the settlement, Ironwood and Allergan will grant Teva a license to market its 145 mcg and 290 mcg generic version of LINZESS in U.S.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Teva Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 23, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Linzess (linaclotide) is the first and only FDA-approved prescription therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation (CIC) in adults and functional constipation (FC) in children and adolescents 6 to 17 years of age.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Linzess (linaclotide) is a guanylate cyclase-C (GC-C) agonist. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. It is being developed for IBS-C or CIC.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
The trial met its primary and secondary endpoints, demonstrating that Linzess (linaclotide) improved frequency of spontaneous bowl movements (SBM) and stool consistency.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Linzess (linaclotide) is a guanylate cyclase-C (GC-C) agonist that is thought to work in two ways based on nonclinical studies. Linaclotide binds to the GC-C receptor locally, within the intestinal epithelium.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Ironwood and AbbVie have reached an agreement with Teva Pharmaceuticals providing a license to Teva's abbreviated new drug application seeking approval to market a generic version of 72 mcg LINZESS® (linaclotide) prior to the expiration of the companies' applicable patents.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 26, 2021
Details:
Linaclotide binds to the GC-C receptor locally, within the intestinal epithelium. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Allergan Aesthetics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
The Phase II trial did not meet its primary or key secondary endpoints. Based on these findings, Ironwood and AbbVie plan to discontinue the development of MD-7246.
Lead Product(s): Linaclotide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
Ironwood is monitoring the ongoing clinical trials for MD-7246 and IW-3718 to assess the impact of COVID-19.
Lead Product(s): Linaclotide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
